| Literature DB >> 31987052 |
Henry Surendra1,2, Riris A Ahmad3,4, Rizqiani A Kusumasari3,5, Theodola B Rahayujati6, Siska Y Damayanti6, Kevin K A Tetteh7, Chetan Chitnis8, Gillian Stresman7, Jackie Cook9, Chris Drakeley7.
Abstract
BACKGROUND: In order to improve malaria burden estimates in low transmission settings, more sensitive tools and efficient sampling strategies are required. This study evaluated the use of serological measures from repeated health facility-based cross-sectional surveys to investigate Plasmodium falciparum and Plasmodium vivax transmission dynamics in an area nearing elimination in Indonesia.Entities:
Keywords: Elimination; Malaria; Mapping; Serology; Surveillance
Mesh:
Year: 2020 PMID: 31987052 PMCID: PMC6986103 DOI: 10.1186/s12916-019-1482-7
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Maps showing the location of Yogyakarta Province in Indonesia (a), location of Kulon Progo District in Yogyakarta Province (b), and the location of eight studied health facilities in Kulon Progo District (c). Tree cover data, derived from classified Landsat imagery at 30-m resolution, were obtained from Hansen et al. [57]
Number of samples, participation rates and general characteristics of health facility attendees per survey
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | Total | |
|---|---|---|---|---|---|
| (May–July) | (August–October) | (November–January) | (February–April) | ||
| Sample size, | 2363 | 2370 | 2379 | 2341 | 9453 |
| Kokap 1 | 299 | 300 | 286 | 300 | 1185 |
| Kokap 2 | 298 | 298 | 297 | 301 | 1194 |
| Samigaluh 1 | 298 | 300 | 298 | 299 | 1195 |
| Samigaluh 2 | 300 | 297 | 300 | 280 | 1177 |
| Kalibawang | 296 | 300 | 298 | 263 | 1157 |
| Girimulyo 1 | 285 | 299 | 300 | 299 | 1183 |
| Girimulyo 2 | 300 | 276 | 300 | 299 | 1175 |
| Pengasih 2 | 287 | 300 | 300 | 300 | 1187 |
| Participation rates | |||||
| Mean % | 95 | 96 | 91 | 96 | 94 |
| Range* | 91–99 | 90–99 | 82–99 | 90–100 | 91–96 |
| Female, | 1578 (66.8) | 1527 (64.4) | 1530 (64.3) | 1502 (64.2) | 6137 (64.9) |
| Age, median (IQR) | 40 (25–54) | 41 (27–54) | 42 (27–55) | 43 (30–57) | 42 (27–55) |
| Patients, | 1803 (76.3) | 1939 (81.8) | 1878 (78.9) | 1812 (77.4) | 7432 (78.6) |
| Occupation, | |||||
| Forest workers | 655 (27.7) | 709 (29.9) | 620 (26.1) | 800 (34.2) | 2784 (29.5) |
| Non-forest workers | 685 (29.0) | 647 (27.3) | 738 (31.0) | 678 (29.0) | 2748 (29.1) |
| Not working | 1023 (43.3) | 1014 (42.3) | 1021 (42.9) | 859 (36.8) | 3917 (41.5) |
| Lives in a house with bed net, | 1091 (46.2) | 1132 (47.8) | 999 (42.0) | 777 (33.3) | 3999 (42.3) |
| Slept under the bed net, | 710 (30.1) | 685 (28.9) | 666 (28.0) | 527 (22.5) | 2588 (27.4) |
| Recent travel, | 595 (25.2) | 581 (24.6) | 211 (8.9) | 111 (4.7) | 1498 (15.9) |
| Fever, | 127 (5.4) | 116 (5.0) | 146 (6.1) | 93 (4.0) | 484 (5.2) |
*Range of health facility-level summaries
Seroprevalence to P. vivax and P. falciparum at quarterly surveys
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |||||
|---|---|---|---|---|---|---|---|---|
| Number positive | Seroprevalence% (95% CI) | Number positive | Seroprevalence % (95% CI) | Number positive | Seroprevalence % (95% CI) | Number positive | Seroprevalence % (95% CI) | |
| Age group | ||||||||
| 1–15 years old | 44 | 12.1 (8.0–17.8) | 24 | 11.2 (7.6–16.2) | 26 | 17.6 (12.2–24.6) | 9 | 10.5 (5.5–18.9) |
| > 15 years old | 1014 | 41.0 (38.9–43.1) | 1000 | 50.1 (47.9–52.3) | 906 | 41.6 (39.6–43.7) | 918 | 41.8 (39.8–43.9) |
| All ages | 1058 | 38.8 (36.8–40.8) | 1024 | 46.3 (44.2–48.3) | 932 | 40.1 (38.2–42.1) | 927 | 40.7 (38.7–42.7) |
| Age group | ||||||||
| 1–15 years old | 6 | 3.4 (1.6–7.5) | 8 | 3.7 (1.9–7.3) | 5 | 3.4 (1.4–7.9) | 1 | 1.2 (0.2–7.8) |
| > 15 years old | 405 | 18.8 (17.3–20.6) | 521 | 26.1 (24.2–28.1) | 489 | 22.6 (20.9–24.4) | 504 | 23.0 (21.3–24.8) |
| All ages | 411 | 17.7 (16.2–19.3) | 529 | 23.9 (22.2–25.7) | 494 | 21.4 (19.8–23.1) | 505 | 22.1 (20.5–23.9) |
Fig. 2Proportion of individuals based on score of age-adjusted antibody responses to multiple a P. vivax and b P. falciparum antigens by survey time. Blue represents proportion of individuals with low age-adjusted antibody responses (score 1), yellow represents average (score 2), orange represents higher than average (score 3) and red represents proportion of individuals with highest age-adjusted antibody responses (score 4)
Fig. 3Age-seroprevalence plots for P. falciparum (a) and for P. vivax (b). Solid lines represent the fitted probability for being seropositive to either of the two or five antigens for P. falciparum and P. vivax, respectively. Dashed lines represent the 95% confidence interval of these fits and red triangles represent the observed proportion of seropositive per age decile. SCR value represents the average annual rate at which the population become seropositive to any of the P. falciparum or P. vivax antigen, respectively
Fig. 4P. vivax age-seroprevalence plots and total number of P. vivax microscopy infections per health facility. Solid lines represent the fitted probability for being seropositive to either of the five P. vivax antigens. Dashed lines represent the 95% confidence interval of these fits and red triangles represent the observed proportion of seropositive per age decile. SCR value represents the average annual rate at which the population become seropositive to any of the P. vivax antigen
Factors associated with P. vivax transmission in Kulon Progo District, Indonesia, 2018
| Variable | Total | Bivariate | Multivariable | ||||
|---|---|---|---|---|---|---|---|
| % (95% CI) | ORa (95% CI) | aORb (95% CI) | |||||
| Age (years) | |||||||
| ≤ 15 | 623 (6.8) | 80 | 12.9 (10.5–15.7) | 1 | 1 | ||
| 16–30 | 2108 (23.1) | 750 | 35.6 (33.6–37.6) | 4.6 (3.6–5.9) | 0.000 | 5.1 (3.9–6.6) | 0.000 |
| 31–45 | 2531 (27.7) | 1115 | 44.1 (42.1–46.0) | 6.5 (5.0–8.3) | 0.000 | 6.6 (5.1–8.7) | 0.000 |
| > 45 | 3880 (42.4) | 1836 | 47.3 (45.8–48.9) | 7.5 (5.9–9.7) | 0.000 | 7.7 (5.9–10.0) | 0.000 |
| Gender | |||||||
| Female | 5945 (65.0) | 2309 | 38.8 (37.6–40.1) | 1 | 1 | ||
| Male | 3206 (35.0) | 1476 | 46.0 (44.3–47.8) | 1.3 (1.2–1.4) | 0.000 | 1.3 (1.2–1.5) | 0.000 |
| Status | |||||||
| Accompanying | 1960 (21.4) | 895 | 45.7 (43.5–47.9) | 1 | |||
| Patients | 7191 (78.6) | 2889 | 40.2 (39.0–41.3) | 0.9 (0.8–1.0) | 0.028 | ||
| Occupation | |||||||
| Non-forest goers | 2653 (29.0) | 1023 | 38.6 (36.7–40.4) | 1 | 1 | ||
| Forest goers | 2685 (29.4) | 1393 | 51.9 (50.0–53.8) | 1.6 (1.4–1.8) | 0.000 | 1.2 (1.0–1.3) | 0.012 |
| Unemployed | 3810 (41.6) | 1368 | 35.9 (34.4–37.4) | 0.9 (0.8–1.0) | 0.011 | 1.0 (0.9–1.1) | 0.446 |
| Survey time | |||||||
| Quarter 1 | 2324 (25.4) | 903 | 38.9 (36.9–40.9) | 1 | 1 | ||
| Quarter 2 | 2217 (24.2) | 1024 | 46.2 (44.1–48.3) | 1.4 (1.2–1.5) | 0.000 | 1.5 (1.3–1.6) | 0.000 |
| Quarter 3 | 2328 (25.4) | 930 | 40.0 (38.0–42.0) | 1.1 (0.9–1.2) | 0.348 | 1.0 (0.9–1.2) | 0.524 |
| Quarter 4 | 2283 (24.9) | 928 | 40.7 (38.6–42.7) | 1.1 (1.0–1.2) | 0.196 | 1.0 (0.9–1.2) | 0.799 |
| Bed net use | |||||||
| No | 6650 (72.7) | 2556 | 38.4 (37.3–39.6) | 1 | 1 | ||
| Yes | 2502 (27.3) | 1229 | 49.1 (47.2–51.1) | 1.2 (1.1–1.3) | 0.000 | 1.2 (1.1–1.3) | 0.001 |
| Fever | |||||||
| No | 8640 (94.9) | 3604 | 41.7 (40.7–42.8) | 1 | |||
| Yes | 465 (5.1) | 164 | 35.3 (31.1–39.7) | 0.6 (0.5–0.8) | 0.000 | ||
| Recent travel | |||||||
| No | 7681 (84.1) | 3171 | 41.3 (39.3–44.4) | 1 | |||
| Yes | 1457 (15.9) | 609 | 41.8 (40.2–42.4) | 0.9 (0.8–1.1) | 0.243 | ||
aBivariate OR adjusted by correlation at a health facility level
bMultivariable OR adjusted by other covariates with bivariate p value < 0.05, and correlation at a health facility level
Quarter 1: May–July 2017, Quarter 2: August–October 2017, Quarter 3: November 2017–January 2018, Quarter 4: February–April 2018
Fig. 5Spatial distribution of age-adjusted antibody responses to multiple P. vivax antigens over time of surveys overlaid with P. vivax microscopy infections captured by the current surveillance systems. Black triangles represent P. vivax microscopy-positive households. Black circle indicates a cluster of significantly higher than expected antibody responses detected using SaTScan (p value < 0.05)